Patents by Inventor Helena Shifrin
Helena Shifrin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230414537Abstract: The present disclosure provides a topical sprayable composition comprising: (a) about 0.05% to about 5% by weight naftifine or pharmaceutical acceptable salt thereof, (b) a film forming agent comprising octylacrylamide acrylate copolymer and, (c) an alcoholic solvent, topical spray composition wherein the ratio of the alcoholic solvent to the propellant in the composition is about 1:1 to about 3:1 (w/w). The disclosure also provides a method of treating a dermatophyte skin infection or onychomycosis in a subject in need thereof, the method comprising topically administering to the subject the topical compositions as described herein.Type: ApplicationFiled: June 21, 2023Publication date: December 28, 2023Inventors: Helena SHIFRIN, Alexandra SHRAIFEL, Ron SCHLINGER, Tzviel SHESKIN, Avi AVRAMOFF
-
Patent number: 11844861Abstract: The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.Type: GrantFiled: September 29, 2021Date of Patent: December 19, 2023Assignee: TARO PHARMACEUTICAL INDUSTRIES LTD.Inventors: Vered Rosenberger, Helena Shifrin, Irena Oleinik, Tzviel Sheskin, Ron Schlinger, Avi Avramoff
-
Publication number: 20230293543Abstract: Embodiments of stable topical compositions for administering fenoldopam (compound (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed for immediate or continued slow release administration, over prolonged periods of time with safe minimal systemic exposure of fenoldopam (reducing the risk for lowering blood pressure). The compositions include those compositions that increase the stability and skin absorption of the drug, particularly anhydrous semi-solid compositions and creams. This is accomplished by incorporating fenoldopam in soluble or dispersed form into semi-solid compositions like ointments or anhydrous gels that are not irritative. Embodiments of methods for using the topical compositions in the treatment of dermatological disorders including psoriasis, alopecia atopic dermatitis and vitiligo are disclosed.Type: ApplicationFiled: January 6, 2023Publication date: September 21, 2023Inventors: Wahid KHAN, Helena SHIFRIN, Ron SCHLINGER, Avi AVRAMOFF, Abraham Jacob DOMB
-
Publication number: 20230248641Abstract: A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.Type: ApplicationFiled: April 4, 2023Publication date: August 10, 2023Inventors: Avi AVRAMOFF, Helena SHIFRIN, Irena OLEINIK, Ron SCHLINGER, Tzviel SHESKIN, Vered ROSENBERGER
-
Publication number: 20230172960Abstract: The present invention relates to a novel and unexpected method of using topical Capecitabine composition to obtain therapeutically effective amounts of fluorouracil (FU) within the skin of a subject afflicted with hyperproliferative or inflammatory skin condition. The method comprising topically administering a pharmaceutical composition comprising Capecitabine or a hydrate or solvate thereof to the affected area of the skin of the subject, to form therapeutically effective amounts of FU within the skin.Type: ApplicationFiled: September 21, 2022Publication date: June 8, 2023Inventors: Avi AVRAMOFF, Helena SHIFRIN, Ron SCHLINGER, Tzviel SHESKIN, Zeev ELKOSHI
-
Patent number: 11612607Abstract: Embodiments of stable topical compositions for administering fenoldopam (compound (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed for immediate or continued slow release administration, over prolonged periods of time with safe minimal systemic exposure of fenoldopam (reducing the risk for lowering blood pressure). The compositions include those compositions that increase the stability and skin absorption of the drug, particularly anhydrous semi-solid compositions and creams. This is accomplished by incorporating fenoldopam in soluble or dispersed form into semi-solid compositions like ointments or anhydrous gels that are not irritative. Embodiments of methods for using the topical compositions in the treatment of dermatological disorders including psoriasis, alopecia atopic dermatitis and vitiligo are disclosed.Type: GrantFiled: August 30, 2017Date of Patent: March 28, 2023Assignee: TARO PHARMACEUTICALS INDUSTRIES LTD.Inventors: Wahid Khan, Helena Shifrin, Ron Schlinger, Avi Avramoff, Abraham Jacob Domb
-
Publication number: 20230059107Abstract: The present disclosure is directed to a topical composition, e.g., a physically and chemically stable topical composition of Fenoldopam comprising about 0.1% to about 5% by weight of Fenoldopam or a pharmaceutically acceptable salt thereof, at least one polyacrylamide-type gelling agent, at least one cellulose-type gelling agent, and at least one solvent, wherein the Fenoldopam is substantially solubilized in the composition, and wherein the composition is stable for at least twelve months at 25° C. and 60% relative humidity.Type: ApplicationFiled: August 9, 2022Publication date: February 23, 2023Inventors: Helena SHIFRIN, Alexandra SHRAIFEL, Vered ROSENBERGER, Ron SCHLINGER, Tzviel SHESKIN, Avi AVRAMOFF
-
Patent number: 11559541Abstract: The present invention relates to a novel and unexpected method of using topical Capecitabine composition to obtain therapeutically effective amounts of fluorouracil (FU) within the skin of a subject afflicted with hyperproliferative or inflammatory skin condition. The method comprising topically administering a pharmaceutical composition comprising Capecitabine or a hydrate or solvate thereof to the affected area of the skin of the subject, to form therapeutically effective amounts of FU within the skin.Type: GrantFiled: January 18, 2019Date of Patent: January 24, 2023Assignee: TARO PHARMACEUTICAL INDUSTRIES LTD.Inventors: Avi Avramoff, Helena Shifrin, Ron Schlinger, Tzviel Sheskin, Zeev Elkoshi
-
Patent number: 11446237Abstract: The present disclosure is directed to a topical composition, e.g., a physically and chemically stable topical composition of Fenoldopam comprising about 0.1% to about 5% by weight of Fenoldopam or a pharmaceutically acceptable salt thereof, at least one polyacrylamide-type gelling agent, at least one cellulose-type gelling agent, and at least one solvent, wherein the Fenoldopam is substantially solubilized in the composition, and wherein the composition is stable for at least twelve months at 25° C. and 60% relative humidity.Type: GrantFiled: March 6, 2020Date of Patent: September 20, 2022Inventors: Helena Shifrin, Alexandra Shraifel, Vered Rosenberger, Ron Schlinger, Tzviel Sheskin, Avi Avramoff
-
Patent number: 11433025Abstract: A waterless foamable pharmaceutical composition suitable for external administration is disclosed. The composition includes a foamable carrier least one liquefied or compressed gas propellant. The foamable carrier includes at least one liquid oil; at least one silicone and at least one least one stabilizing agent; wherein the stabilizing agent selected from the group consisting of about 0.01% to about 25% by weight of at least one surface-active agent alone or on combination with a foam adjuvant; and about 0% to about 5% by weight of at least one polymeric agent alone or on combination with a foam adjuvant; and mixtures thereof. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.Type: GrantFiled: August 17, 2018Date of Patent: September 6, 2022Assignee: Vyne Therapeutics Inc.Inventors: Dov Tamarkin, Helena Shifrin, Rita Keynan, Enbal Ziv, Tal Berman, David Schuz, Elana Gazal
-
Publication number: 20220040089Abstract: The present disclosure is directed to a topical composition, e.g., a physically and chemically stable topical composition of Fenoldopam comprising about 0.1% to about 5% by weight of Fenoldopam or a pharmaceutically acceptable salt thereof, at least one polyacrylamide-type gelling agent, at least one cellulose-type gelling agent, and at least one solvent, wherein the Fenoldopam is substantially solubilized in the composition, and wherein the composition is stable for at least twelve months at 25° C. and 60% relative humidity.Type: ApplicationFiled: March 6, 2020Publication date: February 10, 2022Inventors: Helena SHIFRIN, Alexandra SHRAIFEL, Vered ROSENBERGER, Ron SCHLINGER, Tzviel SHESKIN, Avi AVRAMOFF
-
Publication number: 20220016028Abstract: The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.Type: ApplicationFiled: September 29, 2021Publication date: January 20, 2022Inventors: Vered ROSENBERGER, Helena SHIFRIN, Irena OLEINIK, Tzviel SHESKIN, Ron SCHLINGER, Avi AVRAMOFF
-
Publication number: 20210393613Abstract: The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.Type: ApplicationFiled: August 2, 2021Publication date: December 23, 2021Inventors: Vered ROSENBERGER, Helena SHIFRIN, Irena OLEINIK, Tzviel SHESKIN, Ron SCHLINGER, Avi AVRAMOFF
-
Patent number: 11173117Abstract: The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 ?m, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.Type: GrantFiled: February 2, 2021Date of Patent: November 16, 2021Assignee: TARO PHARMACEUTICAL INDUSTRIES LTD.Inventors: Vered Rosenberger, Helena Shifrin, Irena Oleinik, Tzviel Sheskin, Ron Schlinger, Avi Avramoff
-
Publication number: 20210236423Abstract: The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 ?m, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.Type: ApplicationFiled: February 2, 2021Publication date: August 5, 2021Inventors: Vered ROSENBERGER, Helena SHIFRIN, Irena OLEINIK, Tzviel SHESKIN, Ron SCHLINGER, Avi AVRAMOFF
-
Publication number: 20210052620Abstract: The present invention relates to a novel and unexpected method of using topical Capecitabine composition to obtain therapeutically effective amounts of fluorouracil (FU) within the skin of a subject afflicted with hyperproliferative or inflammatory skin condition. The method comprising topically administering a pharmaceutical composition comprising Capecitabine or a hydrate or solvate thereof to the affected area of the skin of the subject, to form therapeutically effective amounts of FU within the skin.Type: ApplicationFiled: January 18, 2019Publication date: February 25, 2021Inventors: Avi AVRAMOFF, Helena SHIFRIN, Ron SCHLINGER, Tzviel SHESKIN, Zeev ELKOSHI
-
Publication number: 20200237651Abstract: A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.Type: ApplicationFiled: January 9, 2020Publication date: July 30, 2020Inventors: Avi AVRAMOFF, Helena SHIFRIN, Irena OLEINIK, Ron SCHLINGER, Tzviel SHESKIN, Vered ROSENBERGER
-
Patent number: 10548837Abstract: A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.Type: GrantFiled: May 3, 2017Date of Patent: February 4, 2020Assignee: TARO PHARMACEUTICAL INDUSTRIES LTD.Inventors: Avi Avramoff, Helena Shifrin, Irena Oleinik, Ron Schlinger, Tzviel Sheskin, Vered Rosenberger
-
Publication number: 20190328746Abstract: Embodiments of stable topical compositions for administering fenoldopam (compound (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed for immediate or continued slow release administration, over prolonged periods of time with safe minimal systemic exposure of fenoldopam (reducing the risk for lowering blood pressure). The compositions include those compositions that increase the stability and skin absorption of the drug, particularly anhydrous semi-solid compositions and creams. This is accomplished by incorporating fenoldopam in soluble or dispersed form into semi-solid compositions like ointments or anhydrous gels that are not irritative. Embodiments of methods for using the topical compositions in the treatment of dermatological disorders including psoriasis, alopecia atopic dermatitis and vitiligo are disclosed.Type: ApplicationFiled: August 30, 2017Publication date: October 31, 2019Inventors: Wahid KHAN, Helena SHIFRIN, Ron SCHLINGER, Avi AVRAMOFF, Avi DOMB
-
Publication number: 20190091149Abstract: A waterless foamable pharmaceutical composition suitable for external administration is disclosed. The composition includes a foamable carrier least one liquefied or compressed gas propellant. The foamable carrier includes at least one liquid oil; at least one silicone and at least one least one stabilizing agent; wherein the stabilizing agent selected from the group consisting of about 0.01% to about 25% by weight of at least one surface-active agent alone or on combination with a foam adjuvant; and about 0% to about 5% by weight of at least one polymeric agent alone or on combination with a foam adjuvant; and mixtures thereof. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.Type: ApplicationFiled: August 17, 2018Publication date: March 28, 2019Inventors: Dov Tamarkin, Helena Shifrin, Rita Keynan, Enbal Ziv, Tal Berman, David Schuz, Elana Gazal